Filing Details

Accession Number:
0000899243-21-011436
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-03-12 20:00:33
Reporting Period:
2021-03-10
Accepted Time:
2021-03-12 20:00:33
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1403752 Zymeworks Inc. ZYME Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1761853 Ali Tehrani C/O Zymeworks Inc.
1385 West 8Th Avenue, Suite 540
Vancouver A1 V6H 3V9
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Acquisiton 2021-03-10 7,708 $0.00 264,717 No 4 M Direct
Common Shares Disposition 2021-03-10 4,392 $34.95 260,325 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Restricted Stock Unit Disposition 2021-03-10 7,708 $0.00 7,708 $0.00
Common Shares Stock Option (Right to Buy) Acquisiton 2021-03-10 150,000 $0.00 150,000 $34.82
Common Shares Restricted Stock Unit Acquisiton 2021-03-10 25,000 $0.00 25,000 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
15,417 No 4 M Direct
150,000 2031-03-09 No 4 A Direct
25,000 No 4 A Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Shares 55,511 Indirect Held by spouse
Footnotes
  1. Represents common shares issued upon vesting of one third of the restricted stock units ("RSUs") granted on March 10, 2020.
  2. Represents common shares sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs. Pursuant to the terms of the applicable RSU grant agreement (the "Grant Agreement"), effective on the grant date of the RSUs, the Reporting Person irrevocably adopted a 10b5-1 plan pursuant to which the Reporting Person elected to sell shares to cover tax withholding obligations and other applicable fees in accordance with the terms of the Grant Agreement.
  3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.80 to $35.15, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  4. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
  5. The RSUs were granted on March 10, 2020 and vest in three equal annual instalments beginning on March 10, 2021.
  6. Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date.
  7. The RSUs vest in three equal annual installments beginning on March 10, 2022.